Skip to main content
Erschienen in: Virchows Archiv 2/2020

28.01.2020 | Commentary

Aberrant non-canonical WNT pathway as key-driver of high-grade serous ovarian cancer development

verfasst von: Gian Franco Zannoni, Giuseppe Angelico, Angela Santoro

Erschienen in: Virchows Archiv | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Excerpt

Epithelial ovarian cancer (EOC), the deadliest among gynecologic malignancies, is ranked as the fifth leading cause of cancer deaths in females [1]. Based on morphological findings, cellular origins, clinical characteristics, and several molecular genetic/epigenetic alterations, EOC has been subdivided into five main types: high-grade serous (HGSC, 70%), endometrioid (EC, 10%), clear cell (CC, 10%), mucinous (MC, 3%), and low-grade serous carcinomas (LGSC, < 5%) that account for over 95% of cases [2]. HGSCs generally harbor TP53 alterations, a pronounced genomic instability and, also, inherited and somatic BRCA1 and BRCA2 mutations. The other abovementioned cancer types are frequently characterized by mutations in KRAS, BRAF, PTEN, and CTNNB1 (Beta-catenin), and a relatively stable karyotype [2]. …
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2019) Cancer statistics. CA Cancer J Clin 69(1):7–34CrossRef Siegel RL, Miller KD, Jemal A (2019) Cancer statistics. CA Cancer J Clin 69(1):7–34CrossRef
3.
Zurück zum Zitat Arend RC, Londono-Joshi AI, Straughn JM Jr, Buchsbaum DJ (2013) The Wnt/beta-catenin pathway in ovarian cancer: a review. Gynecol Oncol 131:772–779CrossRef Arend RC, Londono-Joshi AI, Straughn JM Jr, Buchsbaum DJ (2013) The Wnt/beta-catenin pathway in ovarian cancer: a review. Gynecol Oncol 131:772–779CrossRef
4.
Zurück zum Zitat Bovolenta P, Rodriguez J, Esteve P (2006) nFrizzled/RIK mediated signalling in axon guidance. Development 133:4399–4408CrossRef Bovolenta P, Rodriguez J, Esteve P (2006) nFrizzled/RIK mediated signalling in axon guidance. Development 133:4399–4408CrossRef
5.
Zurück zum Zitat Veeman MT, Axelrod JD, Moon RT (2003) A second canon. Functions and mechanisms of beta-catenin independent WNT signalling. Dev Cell 5:367–377CrossRef Veeman MT, Axelrod JD, Moon RT (2003) A second canon. Functions and mechanisms of beta-catenin independent WNT signalling. Dev Cell 5:367–377CrossRef
6.
Zurück zum Zitat Pannone G, Bufo P, Santoro A, Franco R, Aquino G, Longo F, Botti G, Serpico R, Cafarelli B, Abbruzzese A, Caraglia M, Papagerakis S, Lo Muzio L (2010) WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep 24:1035–1041PubMed Pannone G, Bufo P, Santoro A, Franco R, Aquino G, Longo F, Botti G, Serpico R, Cafarelli B, Abbruzzese A, Caraglia M, Papagerakis S, Lo Muzio L (2010) WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep 24:1035–1041PubMed
7.
Zurück zum Zitat Polakis P (2007) The many ways of WNT in cancer. Curr Opin Gen Develop 17:45–51CrossRef Polakis P (2007) The many ways of WNT in cancer. Curr Opin Gen Develop 17:45–51CrossRef
9.
Zurück zum Zitat Chen MW, Yang ST, Chien MH, Hua KT, Wu CJ, Hsiao SM, Lin H, Hsiao M, Su JL, Wei LH (2017) The STAT3- miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer. Cancer Res 77(8):1955–1967CrossRef Chen MW, Yang ST, Chien MH, Hua KT, Wu CJ, Hsiao SM, Lin H, Hsiao M, Su JL, Wei LH (2017) The STAT3- miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer. Cancer Res 77(8):1955–1967CrossRef
11.
Zurück zum Zitat Raghavan S, Mehta P, Xie Y, Lei YL, Mehta G (2019) Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. J Immunother Cancer 7(1):190CrossRef Raghavan S, Mehta P, Xie Y, Lei YL, Mehta G (2019) Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. J Immunother Cancer 7(1):190CrossRef
12.
Zurück zum Zitat Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA et al (2019) A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 154(2):294–301CrossRef Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA et al (2019) A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 154(2):294–301CrossRef
Metadaten
Titel
Aberrant non-canonical WNT pathway as key-driver of high-grade serous ovarian cancer development
verfasst von
Gian Franco Zannoni
Giuseppe Angelico
Angela Santoro
Publikationsdatum
28.01.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 2/2020
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-020-02760-5

Weitere Artikel der Ausgabe 2/2020

Virchows Archiv 2/2020 Zur Ausgabe

Neu im Fachgebiet Pathologie